Stem cells and endometrial hyperplasia

Authors

  • Mohamed S. Gad Department of Obstetrics and Gynecology, Faculty of Medicine Minoufia University, Egypt.
  • Bahgat A Elfeky Department of Animal Biotechnology, Genetic Engineering and Biotechnology Research Institute. University of Sadat City.
  • Ahmed M Nofal Department of Obstetrics and Gynecology, Faculty of Medicine Minoufia University, Egypt.

DOI:

https://doi.org/10.54987/jobimb.v2i2.151

Abstract

Endometrial hyperplasia is characterized by a proliferation of endometrial glands that may progress to or coexist with endometrial carcinoma. Previous studies proved the presence of endometrial stem cells that may have a role in endometrial regeneration and may be responsible for proliferative disorders as in endometrial hyperplasia and endometrial carcinoma. The present
study carried out to evaluate the potentiality of Umbilical cord blood Hematopoietic CD34+ and Mesenchymal stem cells to regress endometrial hyperplastic cells proliferation in vitro under certain condition. The Study carried out on 40 Umbilical cord blood samples collected from term delivering women, mononuclear cell were separated. Endometrial samples from the 40 cases (20
normal and 20 cases with endometrial hyperplasia) were collected by dilatation and curettage or by curetting endometrium after hysterectomy operation. Then treatment of the hyperplastic cells with the Mesenchymal stem cells extract and CD34+ Hematopoietic stem cells extract was done. Results showed that both CD34+ Hematopoietic stem cells extract and mesenchymal stem cells
extract both had decreased the rate of growth of endometrial hyperplastic cell culture reaching near to the rate of growth of normal endometrial primary cell culture but the mesenchymal stem cells extract had a higher degree of control making endometrial growth rate nearer to the rate of growth of normal endometrial primary cell culture.

References

McGuckin P and Forraz N. Potential for access to embryonic-like cells from human umbilical cord blood. Cell Prolif. 2008;41,31- 40.

Gluckman E, Koegler G and Rocha V. Human leukocyte antigen. Matching in cord blood transplantation. Semin Hematol. 2005;42:85-90.

Carolin E, Kjiana E, Rachel M, Hong P and Di W. Isolation and Culture of epithelial progenitors and mesenchymal stem cells from human endometrium. Biol Reprod. 2009; 80(6):1136-1145.

Sandoe J and Eggan K. Opportunities and challenges of pluripotent stem cell neurodegenerative disease models. Nat Neurosci. 2013;16:780-789.

Plenge M, Scolnick E and Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov. 2013;12:581-594.

Tanaka A, Woltjen K, Miyake K, Hotta A, Ikeya M, Yamamoto T, Nishino T, Shoji, E, Sehara-Fujisawa A and Manabe Y. Efficient and reproducible myogenic differentiation from human iPS cells: prospects for modeling Miyoshi Myopathy in vitro. PLoS One. 2013; 8:e61540.

Luz-Crawford P, Noël D, Fernandez X, Khoury M, Figueroa F, Carrión F, Jorgensen C and Djouad F. Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. PLoS One. 2012; 7:e45272.

Wang Q, Li X, Luo J, Zhang L, Ma L, Lv Z and Xue L. The allogeneic umbilical cord mesenchymal stem cells regulate the function of T helper 17 cells from patients with rheumatoid arthritis in an in vitro co-culture system. BMC Musculoskelet Disord. 2012;13:249.

Svobodova E, Krulova M, Zajicova A, Pokorna K. Prochazkova J, Trosan P and Holan V. The role of mouse mesenchymal stem cells in differentiation of naive T-cells into anti-inflammatory regulatory T-cell or proinflammatory helper T-cell 17 population. Stem Cells Dev. 2012; 21:901-910.

Tomchuck S, Norton B, Garry F, Bunnell A, Morris A, Freytag C and Clements D. Mesenchymal stem cells as a novel vaccine platform. Front Cell Infect Microbiol. 2012; 2:140.

Li C, Zhang W, Li H, Jiang X, Zhang Y, Tang P and Mao N. Mesenchymal stem cells derived from human placenta suppress allogeneic umbilical cord blood lymphocyte proliferation. Cell Res. 2005; 15: 539-547.

Carrade D, Lame M, Kent M, Clark K, Walker N and Borjesson L. Comparative analysis of the immunomodulatory properties of equine adult-derived mesenchymal stem cells. Cell Med. 2012;4:1-11.

Franquesa M, Hoogduijn M, Bestard O and Grinyó J. Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol. 2012;3:212.

Le Blanc K, Tammik L, Sundberg B, Haynesworth S and Ringdén O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57:11–20.

Downloads

Published

31.12.2014

How to Cite

Gad, M. S., Elfeky, B. A., & Nofal, A. M. (2014). Stem cells and endometrial hyperplasia. Journal of Biochemistry, Microbiology and Biotechnology, 2(2), 70–75. https://doi.org/10.54987/jobimb.v2i2.151

Issue

Vol. 2 No. 2 (2014)

Section

Articles

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).